Novel Cas12a nuclease BEST3 and application thereof
By obtaining and identifying the novel Cas12a protein BEST3, the problems of restricted PAM and low editing activity of the existing CRISPR-Cas12a system in gene editing and nucleic acid detection are solved, achieving wider target site selection and more efficient editing efficiency.
Patent Information
- Application Number
- CN202311773305.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-20
- Publication Date
- 2025-06-20
AI Technical Summary
The existing CRISPR-Cas12a system has problems such as restricted PAM, low editing activity and off-target effects in gene editing and nucleic acid detection, which limits its application scope and efficiency.
Through systematic mining and identification, a novel Cas12a protein is obtained, called BEST3, which has broader PAM recognition characteristics and improved nucleic acid cleavage activity, and is evaluated in combination with bioinformatics, biochemical and cytologic experiments.
BEST3 proteins show significant gene editing activity and nucleic acid detection capabilities in vivo and in vitro, providing a wider selection of target sites and more efficient editing efficiency, solving the problems of PAM restriction and low editing activity in existing systems.